Agilis Biotherapeutics snags $8 mln
According to a news announcement on its site, Agilis Biotherapeutics has closed $8 million in funding. The investors were not named. The financing will be used to develop a treatment for Friedreich's ataxia in partnership with Intrexon Corp. Based in New York, Agilis is a biotech company focused on rare genetic diseases. To read further details about the funding, visit here.
2 January 2014•1 min read
